The Technical Analyst
Pfizer Inc [PFE]
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers—General
Pfizer Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.80% $28.27
America/New_York / 8 mai 2024 @ 16:01
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 159 634 mill |
| EPS: | -0.0500 |
| P/E: | -565.40 |
| Earnings Date: | Jul 30, 2024 |
| SharesOutstanding: | 5 646.78 mill |
| Avg Daily Volume: | 42.46 mill |
| RATING 2024-05-08 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 2/23 | 3/23 | 4/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -565.40 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -23.43x |
| Company: PE -565.40 | industry: PE 24.13 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$62.96 (122.71%) $34.69 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 27.80 - 28.74 ( +/- 1.66%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-30 | Damico Jennifer B. | Buy | 55 | Phantom Stock Units SSP |
| 2024-04-30 | Bourla Albert | Buy | 20 | Phantom Stock Units SSP |
| 2024-04-25 | Quincey James | Buy | 8 116 | Phantom Stock Units |
| 2024-04-25 | Smith James C | Buy | 8 116 | Phantom Stock Units |
| 2024-04-25 | Nora Johnson Suzanne M | Buy | 8 116 | Phantom Stock Units |
| INSIDER POWER |
|---|
| 70.76 |
| Last 100 transactions |
| Buy: 4 322 762 | Sell: 745 543 |
Forecast:
16:00 - $28.28
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $28.28
Forecast 2: 16:00 - $28.28
Forecast 3: 16:00 - $28.28
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $28.27 (1.80% ) |
| Volume | 38.65 mill |
| Avg. Vol. | 42.46 mill |
| % of Avg. Vol | 91.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PFE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest Press Releases
2024-05-06 06:45:00 - Press Release
Pfizer Announces New Chief Strategy And Innovation Officer
New york--(business wire)--pfizer inc. (nyse: pfe) today announced that andrew baum, m.d., will join the company as chief strategy and innovation officer, executive vice president. dr. baum will be a member of pfizer's executive leadership team reporting to chairman and chief executive officer, dr. albert bourla. he joins pfizer from citi, where he served as head of global healthcare, managing director equity research. prior to joining citi in 2011, dr. baum covered european pharmaceuticals at.
2024-05-02 10:00:00 - Press Release
Nussbaum Law Group, P.c. And Roberts Law Firm Us, Pc Announce A $50 Million Class Action Settlement With Pfizer On Behalf Of Direct Purchasers Of Epipen® Or Generic Epipen
New york--(business wire)--nussbaum law group, p.c. and roberts law firm us, pc: court-ordered legal notice united states district court for the district of kansas if you purchased epipen® or generic epipen directly from the manufacturer, you may receive a payment from a $50 million class action settlement with pfizer. kph healthcare services, inc. v. mylan n.v., case no. 2:20-cv-02065-ddc-tjj (district of kansas) this is not a recall, safety, or other similar notice. no one is claiming tha.
2024-05-01 06:45:00 - Press Release
Pfizer Reports First-quarter 2024 Results
New york--(business wire)--pfizer inc. (nyse: pfe) reported financial results for the first quarter of 2024 and raised its adjusted(3) diluted eps guidance while maintaining all other components of its 2024 financial guidance(6). the first-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to pfizer's r&d pipeline can be found at www.pfizer.com. executive commentary dr. albert bourla, chairman and chief executive officer, sta.
2024-04-29 18:40:00 - Press Release
Tivdak® (tisotumab Vedotin-tftv) Receives U.s. Fda Approval To Treat Recurrent Or Metastatic Cervical Cancer
Company announcement full approval based on global phase 3 study demonstrating overall survival benefit of tivdak compared to chemotherapy tivdak is the first antibody-drug conjugate in this patient population to have positive overall survival data copenhagen, denmark; april 30, 2024 – genmab a/s (nasdaq: gmab) and pfizer inc. (nyse: pfe) announced today the u.s. food and drug administration (fda) has approved the supplemental biologics license application (sbla) for tivdak® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. this fda action converts the september 2021 accelerated approval of tivdak to a full approval.
2024-04-29 18:40:00 - Press Release
Fda Grants Full Approval For Tivdak® To Treat Recurrent Or Metastatic Cervical Cancer
New york & copenhagen, denmark--(business wire)--pfizer inc. (nyse: pfe) and genmab a/s (nasdaq: gmab) today announced the u.s. food and drug administration (fda) approves the supplemental biologics license application (sbla) granting full approval for tivdak® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. "recurrent or metastatic cervical cancer is a particularly devastating and mostly incur.
Latest News
2024-05-09 04:37:00 - The Motley Fool
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
Shares of Pfizer offer a 6% dividend yield at recent prices. The pharmaceutical giant has raised its quarterly payout for 15 consecutive years.
2024-05-08 11:57:22 - New York Post
Pfizer agrees to settle over 10K lawsuits linking Zantac to cancer
The lawsuits were filed in state courts nationwide, but the agreements don't completely resolve Pfizer's exposure to claims linking Zantac and cancer.
2024-05-08 10:37:16 - Seeking Alpha
Pfizer: A 6% Yield And At 10-Year Lows
Pfizer's stock has experienced significant fluctuations in the past 4 years, with opportunities for investors to buy low and sell high. The market has driven Pfizer's price to a 10-year low. Pfizer's focus on oncology and its strong pipeline of new products position the company for future growth, although debt obligations may limit dividend increases in the short term.
2024-05-08 09:38:22 - Finbold
Here's why you should buy these 3 stocks and hold them forever
Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack of demand per se.
2024-05-07 17:04:04 - Reuters
Pfizer reports patient death in Duchenne gene therapy study
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told Reuters on Tuesday.
2024-05-07 15:25:38 - Forbes
Pfizer Dividend Yield Pushes Past 6%
In trading on Tuesday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.91 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
2024-05-07 14:04:24 - InvestorPlace
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
2024-05-06 14:22:51 - InvestorPlace
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Investing in dividend stocks is one of the surest paths to building long-term wealth. Those who reinvest dividends compound their returns, building sustainable wealth in the long run.
2024-05-06 10:01:12 - Zacks Investment Research
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2024-05-06 06:10:11 - MarketBeat
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Biopharma giant Pfizer Inc. NYSE: PFE has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to its swing low of $25.20 on April 26, 2024.